Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics
Nassim Usman, Lawrence M. Blatt
Nassim Usman, Lawrence M. Blatt
Published November 15, 2000
Citation Information: J Clin Invest. 2000;106(10):1197-1202. https://doi.org/10.1172/JCI11631.
View: Text | PDF
Perspective Article has an altmetric score of 3

Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics

  • Text
  • PDF
Abstract

Authors

Nassim Usman, Lawrence M. Blatt

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Structure of a general nuclease-resistant ribozyme bound to a generic ta...
Structure of a general nuclease-resistant ribozyme bound to a generic target RNA. The ribozyme consists primarily of 2′-O-Me nucleotides (lower case). The 3′ and 5′ ends are protected by an inverted 3′-3′ deoxyabasic sugar (iB) and four phosphorothioate linkages (s), respectively. The five purine nucleotides (rA or rG) in the catalytic core (shown in green) are required for catalytic activity. A single non-natural carbon containing pyrimidine analog (2′-C-allyluridine) at U4 was used to stabilize the core and maintain activity. The ribozyme binds its cognate target via Watson-Crick base-pairing. In the target strand, cleavage takes place 3′ to the unpaired nucleotide H (H = A, C, or U). This type of ribozyme has an ex vivo serum t1/2 = 10 days.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 2 patents
35 readers on Mendeley
See more details